linkedin post 2013-05-12 22:31:56

MONOCLONAL THERAPIES FOR CANCER CONTINUE TO DOMINATE THE LANDSCAPE. The wave of approvals of MAb treatments for cancer continues unabated. However, does adding a few months to those ghastly survival graphs constitute forward motion in the majority of cases? The personalized medicine approach offers a rational solution by matching the treatment to the tumor’s biology. These individual mutations confer drug resistance or susceptibility, and are becoming the focus of new drug therapies.

http://m.seekingalpha.com/article/1403251-bristol-myers-has-the-future-of-oncology-therapies?source=yahoo

View in LinkedIn